PE-22-28: Side Effects
Known side effects, contraindications, and interactions
📌TL;DR
- •2 known side effects documented
- •0 mild, 0 moderate, 0 severe
- •3 contraindications listed
Compare side effects across multiple peptides →
Side Effects Severity Chart
No human studies have been conducted. The side effect profile is entirely unknown in humans.
TREK-1 channels are involved in neuroprotection against ischemia and pain sensation. Chronic blockade could theoretically increase vulnerability to ischemic injury or alter pain processing.
⛔Contraindications
- •Not approved for human use by any regulatory agency
- •Theoretical concern with cerebrovascular disease (TREK-1 provides neuroprotection during ischemia)
- •Known hypersensitivity to PE-22-28 or any formulation component
⚠️Drug Interactions
- •Theoretical interaction with other potassium channel modulators
- •Potential additive effects with SSRIs or other antidepressants affecting serotonergic transmission
- •Possible interaction with drugs metabolized by pathways affected by TREK-1 channel modulation
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 40+ community reports
View community protocolsImportant Safety Notice#
PE-22-28 has not been tested in humans. All safety information is derived from preclinical mouse studies conducted by a single research group. The human side effect profile is completely unknown.
Preclinical Safety Data#
In the Djillani et al. (2017) study, mice tolerated acute and 4-day sub-chronic PE-22-28 treatment at 3-4 mcg/kg IP without reported adverse effects. However, comprehensive toxicology studies have not been performed, and the publication did not include systematic safety assessments.
Theoretical Safety Concerns#
TREK-1 Blockade Consequences#
TREK-1 potassium channels serve multiple physiological functions beyond mood regulation:
- Neuroprotection: TREK-1 channels are protective during cerebral ischemia. Chronic blockade could theoretically increase vulnerability to ischemic brain injury.
- Pain processing: TREK-1 contributes to pain modulation. Sustained blockade may alter pain sensitivity.
- Thermoregulation: TREK-1 channels are mechanosensitive and thermosensitive, and their blockade could affect temperature sensation.
Limited Safety Database#
The safety database consists of a single mouse study with no dose-ranging, no chronic administration, no organ toxicity assessment, and no reproductive or carcinogenicity studies.
Drug Interactions#
No clinical drug interaction studies exist. Theoretical interactions include additive effects with serotonergic antidepressants and interactions with other potassium channel modulators.
Safety Profile Context#
PE-22-28 belongs to the Neuropeptide category of research peptides. Understanding the side effect profile of PE-22-28 is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.
Reported Side Effects#
The following side effects have been documented in clinical studies of PE-22-28. Side effect severity and frequency are based on available clinical data.
Unknown human side effect profile#
Severity: unknown | Frequency: unknown
No human studies have been conducted. The side effect profile is entirely unknown in humans.
Potential effects from TREK-1 blockade#
Severity: theoretical | Frequency: unknown
TREK-1 channels are involved in neuroprotection against ischemia and pain sensation. Chronic blockade could theoretically increase vulnerability to ischemic injury or alter pain processing.
Contraindications#
The following contraindications have been identified for PE-22-28 based on available research and pharmacological considerations:
- Not approved for human use by any regulatory agency
- Theoretical concern with cerebrovascular disease (TREK-1 provides neuroprotection during ischemia)
- Known hypersensitivity to PE-22-28 or any formulation component
Individuals with any of these conditions should not use PE-22-28 without consulting a qualified healthcare provider.
Drug Interactions#
The following potential drug interactions have been identified for PE-22-28:
- Theoretical interaction with other potassium channel modulators
- Potential additive effects with SSRIs or other antidepressants affecting serotonergic transmission
- Possible interaction with drugs metabolized by pathways affected by TREK-1 channel modulation
Drug interaction studies for PE-22-28 remain limited. Researchers should exercise caution when combining PE-22-28 with other compounds and consult relevant pharmacological references.
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About PE-22-28
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.